Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | SVP, Chief Legal Officer | July 15, 2026 | July 23, 2026 |
| Butterfly Network, Inc.BFLY · Entity 4467 | CLO, GC and Corp Sec | July 05, 2023 | July 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 15, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,618 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 21,288 · Balance 112,618 F1: The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030. |
| Performance RightSEC Table II · derivative / convertible security | Direct | 21,288 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Grant · Acquired 21,288 · Balance 21,288 F2: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
F2: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
Butterfly Network, Inc.
Report date July 05, 2023 · Filed July 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,236,838 |
Reported balance
After 2023-07-05 transaction · row 1
1 source rowRow 1 · 2023-07-05 · Sale · Disposed 27,655 · Balance 1,236,838 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and intended to qualify under Rule 10b5-1. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.15 to $2.315 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and intended to qualify under Rule 10b5-1.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.15 to $2.315 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 22, 2026 00:36 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 2,267 | $14.14 | $32,055.38 |
DisclosureSEC source: 0001140361-26-029190 · form4.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,330 F1 · shares: The exempt disposition of 2,267 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025. Read SEC document |
| July 15, 2026 Filed Jul 23, 2026 00:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 21,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029330 · form4.xml · derivative · entry 2 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,288 Underlying: Common Stock · 21,288 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 15, 2026 Filed Jul 23, 2026 00:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 21,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029330 · form4.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,618 F1 · shares: The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 11:00 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | PurchaseCommon Stock | 10,000 | $11.81 | $118,100.00 |
DisclosureSEC source: 0001140361-25-038873 · form4.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,597 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.71 to $11.90, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 22:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 30,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026463 · form4.xml · derivative · entry 2 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,900 Underlying: Common Stock · 30,900 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 22:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 30,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026463 · form4.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,597 F1 · shares: The acquisition of 30,900 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 30,900 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:33 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 103,650 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001140361-24-048416 · form4.xml · derivative · entry 2 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,650 Underlying: Common Stock · 103,650 shares Expires 2034-12-02 F2 · shares: These stock options vest in four equal annual installments beginning on December 2, 2025, such that 25% of the options will vest on each of December 2, 2025, 2026, 2027 and 2028. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:33 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 52,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-048416 · form4.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,697 F1 · shares: The acquisition of 52,697 shares of common stock ("Common Stock") of AngioDynamics, Inc.("AngioDynamics") represents 52,697 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on December 2, 2025, such that 25% of the restricted stock units will vest on each of December 2, 2025, 2026, 2027 and 2028. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 21:44 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | SaleClass A Common Stock | 27,655 | $2.19 | $60,509.14 |
DisclosureSEC source: 0001104659-23-078836 · tm2320777-1_4seq1.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · CLO, GC and Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,236,838 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.15 to $2.315 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:17 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | SaleClass A Common Stock | 52,296 | $2.22 | $116,076.20 |
DisclosureSEC source: 0001104659-23-065477 · tm2317164-1_4seq1.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · CLO, GC and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,264,493 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.16 to $2.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 452,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002439 · primarydocument.xml · nonDerivative · entry 2 Weiss Lawrence T · CIK 0001930293 · CLO, GC and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,316,789 F2 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33.33% on each anniversary of the grant date, subject to Mr. Weiss's continued service through the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 174,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002439 · primarydocument.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · CLO, GC and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,789 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 50% on July 1, 2023 with the remainder vesting on January 1, 2024, subject to Mr. Weiss's continued service through the applicable vesting date. Read SEC document |
| May 23, 2022 Filed May 24, 2022 20:16 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 690,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-064245 · tm2216668-2_4seq1.xml · nonDerivative · entry 1 Weiss Lawrence T · CIK 0001930293 · CLO, GC and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,789 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Class A common stock upon vesting. The RSUs vest as to 25% on May 23, 2023, with the remainder vesting in three equal annual installments thereafter, subject to Mr. Weiss's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.